Agilent Technologies, Inc. (A)
NYSE · Santa Clara, California, USA · Founded 1999 · CEO Padraig McDonnell
Valuation summary
$107.31 fair value versus $175.34 in the market, a difference of -38.8%. Rated Sell.
| Fair value per share | $107.31 |
| Current share price | $175.34 |
| Upside / downside | -38.8% |
| Bear case | $69.70 |
| Bull case | $161.06 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $49B |
| EV / Sales | 7.1x |
About Agilent Technologies, Inc.
Spun out of Hewlett-Packard in 1999. Padraig McDonnell became CEO in 2025. Agilent makes analytical instruments — mass spectrometers, chromatography systems — used in pharmaceutical development, environmental testing and food safety, plus the consumables and services that go with them. Like Thermo Fisher it sells into research activity rather than betting on outcomes.
Investment case
- Recurring consumables and service revenue is over half the total and far steadier than instruments.
- The installed base of instruments creates a long service annuity.
- Pharmaceutical quality control testing is non-discretionary regulated spending.
Key risks
- Instrument purchases are capital decisions customers defer easily when budgets tighten.
- China is a meaningful market and has been persistently weak.
- Academic and biotech funding pressure has reduced research spending.
Recent developments
- 2026-09-08 · Board chair Koh Boon Hwee retired; Dow Wilson became chair effective 4 September 2026 and Glenn Boehnlein joined the board. source
- 2026-08-26 · Fiscal Q3 2026 revenue $1.88bn, up 8.1% (7.3% core), non-GAAP EPS $1.62, up 18%; full-year EPS guidance raised to $6.18-6.21. source
Revenue by segment
| Life Sciences & Applied Markets | 40% |
| Diagnostics & Genomics | 27% |
| CrossLab Services | 33% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $8.0B | $1.6B |
| Year 2 | $8.7B | $1.7B |
| Year 3 | $9.4B | $1.8B |
| Year 4 | $10.2B | $1.9B |
| Year 5 | $11.1B | $2.1B |
What the street says
A quality instruments franchise that is now recovering. Fiscal third-quarter 2026 core revenue grew 7.3% and full-year guidance was raised to $7.49–$7.51 billion of revenue and $6.18–$6.21 of non-GAAP EPS, so the debate has moved from recovery timing to how durable the upturn is.
Comparable companies: IDXX · RMD · EW · ABT · SYK · TMO · BSX · SNY
Open the interactive model, price chart and sensitivity grid →